1.30

0.00% 0.00

Sonoma Pharmaceuticals Inc (SNOA)

Overview News Price History Financials Why SNOA Down? Discussions Forecast Stock Split

Sonoma Pharmaceuticals Inc stock is traded at $1.30, with a volume of 134.38K. It is up +0.00% in the last 24 hours and up +7.44% over the past month. Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Previous Close:

$1.30

Open:

$1.33

24h Volume:

134.38K

Relative Volume:

0.82

Market Cap:

$6.22M

Revenue:

$19.53M

Net Income/Loss:

$-3.18M

P/E Ratio:

-0.6886

EPS:

-1.888

Net Cash Flow:

$-4.13M

1W Performance:

+0.78%

1M Performance:

+7.44%

6M Performance:

-54.06%

1Y Performance:

-75.70%

1-Day Range:

$1.27

$1.338

1-Week Range:

$1.27

$1.42

52-Week Range:

$0.8501

$5.60

Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile

Name

Sonoma Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

800-759-9305

Address

5445 CONESTOGA COURT, SUITE 150, BOULDER, CA

Employee

260

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

SNOA's Discussions on Twitter

Compare SNOA vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNOA Sonoma Pharmaceuticals Inc	1.30	6.22M	19.53M	-3.18M	-4.13M	-1.888
TAK Takeda Pharmaceutical Co Adr	17.36	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.48	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.5825	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.72	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	507.49	21.43B	3.17B	1.29B	1.01B	27.09

Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News

Aug 06, 2026

Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Nigeria

Aug 06, 2026

Sonoma Pharmaceuticals reports 60% revenue growth in Q1 - Investing.com

Aug 06, 2026

Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive - TradingKey

Aug 06, 2026

Sonoma Pharmaceuticals Q1 revenue rises on US growth - TradingView

Aug 06, 2026

BRIEF-Sonoma Pharmaceuticals Q1 Operating Expenses USD 2.6 Million - TradingView

Aug 06, 2026

Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan

Aug 06, 2026

Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary - TradingView

Aug 06, 2026

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - TradingView

Aug 06, 2026

Aug 05, 2026

Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsStop Loss Guidance - dars.gov.et

Aug 05, 2026

SNOA Q1'26 Earnings: EPS estimate is (0.30) USD - TradingView

Aug 05, 2026

Jul 29, 2026

Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com South Africa

Jul 29, 2026

Jul 28, 2026

Sonoma Pharmaceuticals (Nasdaq: SNOA) 2026 pay, board and auditor votes - Stock Titan

Jul 28, 2026

Jul 27, 2026